Datopotamab Deruxtecan
Non-Small Cell Lung Carcinoma
Explore 1,128 assets in Non-Small Cell Lung Carcinoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
antibody_drug_conjugate
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07535437CT.gov A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07291037CT.gov Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT06822543CT.gov A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) | — | Recruiting | — | — | — |
NCT07098338CT.gov A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06676917CT.gov Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases | — | Withdrawn | — | — | — |
NCT06564844CT.gov A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | — | Active Not Recruiting | — | — | — |
NCT06417814CT.gov A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06350097CT.gov Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06357533CT.gov Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT05555732CT.gov Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | — | Active Not Recruiting | — | — | — |
Show 14 more trialsShow fewer
NCT05687266CT.gov Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | — | Active Not Recruiting | — | — | — |
NCT05460273CT.gov A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | — | Active Not Recruiting | — | — | — |
NCT05061550CT.gov Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05215340CT.gov Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | — | Active Not Recruiting | — | — | — |
NCT05117476CT.gov A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04940325CT.gov Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04484142CT.gov Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | — | Completed | — | — | — |
NCT04612751CT.gov Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04656652CT.gov Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | — | Active Not Recruiting | — | — | — |
NCT04644068CT.gov Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | — | Active Not Recruiting | — | — | — |
NCT04526691CT.gov Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | — | Active Not Recruiting | — | — | — |
NCT03944772CT.gov Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | — | Active Not Recruiting | — | — | — |
NCT03401385CT.gov First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | — | Active Not Recruiting | — | — | — |
NCT06279728CT.gov Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Datopotamab Deruxtecan (this asset) | Memorial Sloan Kettering Cancer Center | P3 | B · 63 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Datopotamab Deruxtecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stomatitis | — | P4 | B · 61 |
| Biliary Tract Cancer | — | P2 | B · 60 |
| Breast Cancer | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Datopotamab Deruxtecan in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/datopotamab-deruxtecan-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →